Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Meridian Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units, indicating a divided technical focus for their current prosecution. The presence of 2 distinct art units suggests that the company's pharmaceutical or biotechnological claims are being reviewed by different specialized groups. This structure requires the company to address the specific standards of two different art units simultaneously, even though the overall volume of active prosecution is low.
CUNNINGCHEN, KATHLEEN MARY is the busiest examiner for the company, currently managing 1 pending office action. With 2 pending office actions in total, the workload is split evenly between the 2 distinct examiners. This lack of concentration means that no single examiner dominates the company's patent strategy. Practitioners should prepare for distinct procedural styles, as each of the 2 distinct examiners will apply their own interpretation of the Biotechnology & Pharmaceuticals standards to the pending applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEIDNER, ADAM M | 1 | 63.7% | +33.6% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574219 | A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using Same | WEIDNER, ADAM M | — |
| 18574224 | COMPOSITIONS AND METHODS OF TREATING PLASMA CELL DISORDERS INCLUDING MULTIPLE MYELOMA WITH A VACCINE COMPOSITION AND MYELOMA-SPECIFIC CAR-T CELLS | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574219 | A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using Same | WEIDNER, ADAM M | — |
| 18574224 | COMPOSITIONS AND METHODS OF TREATING PLASMA CELL DISORDERS INCLUDING MULTIPLE MYELOMA WITH A VACCINE COMPOSITION AND MYELOMA-SPECIFIC CAR-T CELLS | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574219 | A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using Same | WEIDNER, ADAM M | 1675 | §102§103§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18574224 | COMPOSITIONS AND METHODS OF TREATING PLASMA CELL DISORDERS INCLUDING MULTIPLE MYELOMA WITH A VACCINE COMPOSITION AND MYELOMA-SPECIFIC CAR-T CELLS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§112 | Non-Final OA | — | Pending | Dec 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMeridian Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Adam M Weidner has the most, with 1 of Meridian Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
